39
2022Solaris Health
AGENCY STATEMENT
We are a strategically-focused medical communications agency operating globally in areas of unmet medical need. We combine science, insight and creativity to deliver compelling programmes that change medical practice.

- Agency description
Solaris Health thrives in areas of unmet medical need. We’re inspired by the chance to deliver exceptional work in rare, specialist and niche conditions. We’ve worked with many of our clients for years because they value us as true strategic partners who bring imagination, experience, and empathy to their brands.
We delight in the detail and understand the unique combination of scientific rigour and creativity that generates engaging programmes that will change medical practice and impact on patients’ lives.
vivacity is a division of Solaris Health, and we bring a vibrancy to health and wellness brand, HCP and patient communications. We deliver insightful strategies and standout campaigns full of richness and life, all driven by the team’s passion and energy.
Our group includes RJW & partners which is one of the most recognised and respected specialist providers of pricing and market access thinking and solutions. RJW works almost exclusively with prescription pharmaceuticals conducting research across the globe, in virtually all therapy areas and at all lifecycle stages. Projects include pricing strategy assessment and development, evidence planning and gap analysis, innovative pricing agreements and contracting solutions and payer communications and tools which they develop together with Solaris Health.
- Contact details
- The Old Sawmill, Filleigh, Barnstaple EX32 0RN
- 0208 332 2222
- Hello@solarishealth.com
- https://solarishealth.com/
- Key contact
- CLAIRE DOBBS
- Chief Executive
- claire.dobbs@solarishealth.com
- 0208 332 2222
- 2022 Agency Data
-
2021 awardsTotal staff10-24 staffBillings from UK creative healthcare workHealthcare staff10-24 staffTotal agency billingsAgency ageBetween 15 and 20 yearsSocial media footprintStatusNETWORKEDApproximate percentage of advertising, branding, creative or design work in the UK healthcare market10-19%
- This information was supplied or confirmed by Solaris Health. Bar charts are indicative only, with 100% being the maximum score allocated across all agencies. Billings from UK creative healthcare work are not a subset of total annual billings, and so may show a higher rating.
- Ranking factors contributing to agency score
- This chart shows the relative factors that contributed to the agency's overall ranking.
Latest content from Solaris Health on PMHub
- Solaris Health looks at the gene therapy revolution
- Gene therapies are bringing new hope for many people with diseases caused by genetic disorders
Solaris Health - Shaking up healthcare convention: Regenerative medicine and biosimilars impact health economy
- See our Thought Leadership article reviewing pressures at both end of the cost spectrum and considering the likely impact on clinicians and patients.
Solaris Health - Innovation in pharma: the highs and lows of the current healthcare economy
- While the likely premium price of upcoming genetic and cell-based therapies challenges traditional NHS funding mechanisms, the continuing influx of biosmilars is driving down the cost of biologics.
Marian Byrt looks at the challenges at both ends of the spectrum.
Solaris Health



COVID-19 Updates and Daily News
- Early Access Program - Regulatory Affairs (EAP-RA)
- Highly competitive salary
-
Senior Medical Writer
- Highly competitive salary
-
Technical Sales Representative
- Highly competitive salary
-
Pharmacovigilance Manager
- Highly competitive salary
-
Omnichannel Account Director
- £55,000 - £65,000 yearly
-
Pharmacovigilance Project Lead
- Highly competitive salary
- Strategy Director - Healthcare Advertising
- Highly competitive salary
- Associate Director - Global Healthcare Consulting
- Highly competitive salary
Quick links
Latest intelligence
- Improving cardiovascular disease care and awareness
- Scott Curley talks to PME about the risks of CVD and the importance of getting the right treatment at the right time...
- Our client wanted to better understand the needs, preferences, and treatment gaps among adult patients with a rare genetic disease......
- Paul Hutchings, founder of fox&cat, writes on the role of humour in healthcare comms: PharmaComms 2023...
- MHRA to introduce new UK clinical trials framework
- AbbVie’s Parkinson’s disease therapy application rejected by FDA
- Roche and Eli Lilly to collaborate on Alzheimer’s disease blood test
- Takeda presents positive phase 2b results for TAK-279 in plaque psoriasis
- FDA proposes improvements for oncology clinical trials supporting accelerated approval
- Novo Nordisk and Dewpoint partner on insulin resistance drug candidates
- MSD’s Keytruda to be made available in England for advanced cervical cancer patients
- Boehringer Ingelheim and Covant to collaborate on cancer immunotherapies
- Eli Lilly increases investment to almost $1bn for new Irish manufacturing facility
- Regeneron and Sonoma Biotherapeutics partner on autoimmune disease therapies
- Improving cardiovascular disease care and awareness
- PMGroup announces launch of new recruitment platform PharmaRole
- Team ITG appoints Gerhard Arnhofer as head of customer strategy for life sciences division
- Locus Biosciences announces first patient treated in urinary tract infection trial
- The state of pharma customer experience
- MHRA to introduce new UK clinical trials framework
- Takeda presents positive phase 2b results for TAK-279 in plaque psoriasis
- Sanofi/Regeneron’s Dupixent approved by EC for atopic dermatitis in children
Research Partnership
Research Partnership, an Inizio Advisory Company, is a world-leading custom and syndicated global insights partner for health and life science...